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carina and mediastinum) were recorded. Furthermore, the number of 
fractions impossible to evaluate was recorded.  
Results: For all patients, differences were found between match on 
bones and match on soft tissue - mean 3D vector: 3.3 mm (range 1.9 
to 7.7 mm). The number of fractions showing deviations larger than 5 
mm decreased when using match on the soft tissue instead of bones. 
The only exception was columna where deviations larger than 5 mm 
increased from 3 % of the fractions matching on bones to 10 % of the 
fractions matching on soft tissue. Tumour and lymph nodes in the 
mediastinum were difficult to evaluate in 37 % of the fractions. In 
most cases, the reason for occurring deviations were due to changes 
in the mediastinum (tumour shrinkage, atelectasis, pleural effusion), 
or due to rotations of the patient. A second evaluation was performed 
using delineated surrogate structures in the mediastinum 
(e.g.trachea). This resulted in only 9 % of the fractions being 
impossible to evaluate. It was possible to evaluate the normal tissue 
in all cases. 
Conclusions: This study shows that implementing match on soft tissue 
using daily CBCT is possible, and education of the RTTs is important. It 
is necessary to define the match structures by contouring appropriate 
surrogate structures in the mediastinum for the guidance. A larger 
margin to the spinal cord is preferable. 
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Purpose/Objective: The verification of the set-up of patients treated 
for esophageal cancer recently changed from portal imaging to 
Conebeam CT (CBCT) in our department. The protocol, registration on 
the bony anatomy and using an off line decision rule, remained the 
same. As the use of CBCT and experience grew, it became apparent 
that the CBCT scans contained more information about the patient. 
Besides information of patient set-up also soft tissue changes became 
visible. The purpose of this study is to score soft tissue changes during 
treatment of esophagus that have an impact on GTV coverage or may 
alter the dose distribution. 
Materials and Methods: Twenty seven patients with an esophagus 
carcinoma are included in this study. Patients had either preoperative 
or definitive chemoradiotherapy with 23x1.8 Gy or 28x1.8 Gy 
respectively. Both groups had once weekly carboplatin and paclitaxel. 
CBCTscans were acquired for position verification and used for an 
extended No Action Level correction protocol (eNAL): 4 scans in the 
first week and weekly follow-up. Inter-fractionanatomical changes 
were determined for a period of 4 weeks in all patients: for the first 
week only the second scan was evaluated. Soft tissue changes were 
assessed after performing a full registration (6 degrees of freedom) 
using XVI 4.2 (Elekta, Sweden). Changes that caused the GTV to be 
outside of PTV were scored. Furthermore we scored any change in 
anatomy between CT en CBCT larger than 1cm, e.g. change in 
circumference, pleural effusion and atelactasis. 
Results: Results are summed in table 1. In 7% of the patients a GTV 
shift outside the PTV was found inthe third week, 15% in the fourth 
week. In all cases the GTV shift occurred at the right lateral side. The 
most prominent soft tissue change that we encountered was a change 
of the heart contour. In the first week this was visible in 15% of 
patients and in the fourth week in 67% of the patients. One patient 
showed a decrease in body diameter more than 1 cm at the level of 
thePTV. Pleural effusion was observed in one patient in the fourth 
week. 
Conclusions: Results are showing that the PTV margin is exceeded by 
a shift of the GTV in a substantial part of the group. These shifts 
occurred on the right lateral side. We have to underline that we 
assessed changes after a full registration and other uncertainties, such 
as rotational errors which can not be corrected for during treatment, 
were not taken into account. 
Soft tissue changes occur frequently over the course of radiotherapy 
treatment. The effecton the dose distribution needs to be studied. 
Changes in the volume of the heart and its determinants are subject 
of further investigation.  
Using 3D kV-imaging for position verification as well as for tracking 
anatomical changes during treatment is highly recommended.  
   
OC-0446   
Evaluation and development of an IGRT protocol for prostate and 
nodes radiotherapy 
N. Hutton1, A. Carver2, A. Baker1 
1Clatterbridge Cancer Centre, Radiotherapy, Wirral, United Kingdom  
2Clatterbridge Cancer Centre, Physics, Wirral, United Kingdom  
 
Purpose/Objective: Around 40% of patients treated radically for 
clinically localised prostate cancer, suffer from biochemical failure 
within 5 years, possibily, suggesting poor nodal coverage 1. A lack of 
data exists relating to the relationship of prostate and pelvic node 
motion resulting in larger margins than for standard prostate only 
treatments coupled with conservative dose schedules.  
As a sub study of the PIVOTAL trial 2 (prostate only versus prostate and 
nodes) this project aims to investigate the relationship between 
prostate and lymph node motion and to determine if current 
radiotherapy planning margins are appropriate based on the results. 
Materials and Methods: 297 kV imaging sessions have been analysed 
over a 6 month period.The prostate position was quantified based on 
the position of fiducial markers,the nodal position was quantified 
based on bone anatomical registration. Individual and population 
random and systematic errors were calculated using the definitions in 
the on-target document3. The statistical significance of systematic 
errors was determined using the F-test. A T-test and two-sided t-test 
was used to quantify the errors.  
Results: In both prostate and prostate and node arms there was no 
statistically significant difference between matching using fiducial 
markers or bony anatomy. This suggests fiducial markers can be used 
for matching with the confidence that the bony anatomy will be 
within a 5 mm tolerance. 
33 % of patients had at least 1 fraction where a significant difference 
(>5 mm) between fiducial and bone match was observed. 1 patient 
had this difference in almost 30%of fractions, cone beam CT 
verification demonstrated that both target volumes were adequately 
covered when a 5 mm difference in fiducial and bone registration was 
observed. 
The ranges of random and systematic errors are shown below: 
 
  
Conclusions: These early results are contrary to the evidence base, 
possibly due to the use of bladder and bowel preparation for this 
patient group. Based on early results the margins used within the 
PIVOTAL trial will be acceptable providing the strict on-line imaging 
protocol in combination with the bladder and bowel protocol is 
followed. 
1. Han M, Partin AW, Zahurak M et al 2003. Biochemical (prostate 
specific antigen) recurrence probability following radical 
prostatectomy for clinically localised prostate cancer. J Urol.169:517-
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2. PIVOTAL– A randomised phase II trial of prostate and pelvis versus 
prostate alone treatment for locally advanced prostate cancer. Chief 
Investigator: David Dearnaley, Sponsor: Institute of CancerResearch 
 
 
 
